ProShares Ultra Health Care (RXL)
| Assets | $89.26M |
| Expense Ratio | 0.95% |
| PE Ratio | n/a |
| Shares Out | 1.70M |
| Dividend (ttm) | $0.74 |
| Dividend Yield | 1.43% |
| Ex-Dividend Date | Dec 24, 2025 |
| Payout Frequency | Quarterly |
| Payout Ratio | n/a |
| Volume | 10,556 |
| Open | 52.34 |
| Previous Close | 51.81 |
| Day's Range | 51.81 - 52.43 |
| 52-Week Low | 36.23 |
| 52-Week High | 55.44 |
| Beta | 1.22 |
| Holdings | 67 |
| Inception Date | Jan 30, 2007 |
About RXL
Fund Home PageThe ProShares Ultra Health Care (RXL) is an exchange-traded fund that is based on the S&P Health Care Select Sector index. The fund provides 2x leveraged exposure to a cap-weighted index of US health care companies. RXL was launched on Jan 30, 2007 and is issued by ProShares.
Top 10 Holdings
155.22% of assets| Name | Symbol | Weight |
|---|---|---|
| HEALTH CARE SELECT SECTOR INDEX SWAP UBS AG | n/a | 46.89% |
| HEALTH CARE SELECT SECTOR INDEX SWAP GOLDMAN SACHS INTERNATIONAL | n/a | 33.58% |
| HEALTH CARE SELECT SECTOR INDEX SWAP CITIBANK NA | n/a | 19.03% |
| HEALTH CARE SELECT SECTOR INDEX SWAP SOCIETE GENERALE | n/a | 15.17% |
| Eli Lilly and Company | LLY | 11.06% |
| HEALTH CARE SELECT SECTOR INDEX SWAP BNP PARIBAS | n/a | 10.53% |
| Johnson & Johnson | JNJ | 6.46% |
| AbbVie Inc. | ABBV | 5.23% |
| UnitedHealth Group Incorporated | UNH | 3.88% |
| Merck & Co., Inc. | MRK | 3.39% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Dec 24, 2025 | $0.18376 | Dec 31, 2025 |
| Sep 24, 2025 | $0.20313 | Sep 30, 2025 |
| Jun 25, 2025 | $0.21928 | Jul 1, 2025 |
| Mar 26, 2025 | $0.13435 | Apr 1, 2025 |
| Dec 23, 2024 | $0.14718 | Dec 31, 2024 |
| Sep 25, 2024 | $0.12875 | Oct 2, 2024 |
Performance
RXL had a total return of 19.98% in the past year, including dividends. Since the fund's inception, the average annual return has been 14.70%.
News
ProShares and ProFunds Announce Benchmark Changes for 53 Geared Sector Funds
BETHESDA, Md.--(BUSINESS WIRE)--ProShares and ProFunds, premier providers of leveraged and inverse funds, announced plans to change the underlying indices for a combined 53 sector ETFs and mutual fu...
Biotech Innovations Remain At Forefront
The first quarter of 2021 was challenging for the biotechnology industry, as the selloff in March represented a sharp reversal from record highs in February. While the sector has remained relatively r...
Healthcare: A Wide Choice Of Large And Well-Established Companies
The advantage for dividend investors in this sector is the wide choice of large and well-established companies. AbbVie is a drug company with strong exposure to the immunology and the oncology markets...
RXL Is The Best Healthcare ETF Wealth-Builder Now
RXL Is The Best Healthcare ETF Wealth-Builder Now